SS
ORKA

Steve Schonfeld’s Oruka Therapeutics ORKA Stock Holding History

Steve Schonfeld’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
+34,860
New +$2.32M 0.01% 815
2020
Q4 		– Sell
-1,517
Closed -$80K – 1933
2020
Q3 		$80K Buy
+1,517
New +$107K ﹤0.01% 1287

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Steve Schonfeld's ORKA Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 34,860 shares worth $3.32M. The stake represents 0.01% of the portfolio and ranks #815 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in ORKA as recently as Q3 2020.

Steve Schonfeld first reported a position in ORKA in Q3 2020 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Steve Schonfeld held 34,860 shares of Oruka Therapeutics worth $3.32M as of Q2 2026.
  • Oruka Therapeutics was a new Steve Schonfeld position in Q2 2026.
  • Oruka Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #815 holding.
  • Steve Schonfeld first reported a position in Oruka Therapeutics in Q3 2020 and has held it in 2 quarters since.
  • 254 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.